NCT06422806 2026-04-14
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
8 trialsNCT06881992 2026-04-14
Tumor HI
Rezolute
Phase 3 Recruiting
NCT05711615 2026-04-13
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06498648 2026-04-13
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06541262 2026-04-09
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT04715191 2026-04-06
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Recruiting
NCT06975293 2026-04-06
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
STORM Therapeutics LTD
Phase 1/2 Recruiting
NCT04031677 2026-03-31
STRASS2
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting